Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Drug

General health

Online since 15 March 2025, updated 98 days ago

About this trial

This phase 4 trial is enrolling 50 participants with chronic spinal cord injury and type 2 diabetes to test the effect of semaglutide, a drug that helps regulate blood sugar by stimulating insulin release. If included, participants will be randomly assigned to self-administer a weekly injection of either semaglutide or a placebo for 24 weeks. There will be 7-9 in-person visits and 9-10 phone visits. Final testing for glucose levels and weight loss will be performed after 24 weeks.

Included participants

Gender

All

Age

18 - 70 years

Injury level

C2 - L2

Severity (AIS)?

AIS-A

AIS-B

AIS-C

AIS-D

Time since injury

≥ 12 months

Healthy volunteers

C2-L2

Additionally, participants must

be diagnosed with 2 diabetes (T2DM)

What’s involved

Type

Drug

Details

- Participants will be randomly assigned to self-administer either semaglutide or a placebo as a weekly injection for 24 weeks. - Semaglutide is a drug that helps regulate blood sugar by stimulating insulin release. - Final testing will be performed after 24 weeks.

Potential benefits

Main benefits

General health

Additional benefits

Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.

Wings for Life supports SCITrialsFinder

Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.

Learn more

Back to results